Welcome to our dedicated page for Pavmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (PAVM) is a commercial-stage medical technology leader driving innovation in diagnostic testing, medical devices, and digital health solutions. This dedicated news hub provides investors and industry professionals with timely updates on corporate developments, clinical milestones, and strategic initiatives shaping the future of preventive care technologies.
Access official press releases, earnings reports, and regulatory filings in one centralized location. Our curated collection features updates on product commercialization progress, FDA clearances, and partnership announcements, enabling stakeholders to track the company’s execution of its rapid concept-to-market strategy across multiple healthcare sectors.
Key content categories include financial performance updates, new product launches, clinical study results, and executive leadership developments. The resource is particularly valuable for monitoring advancements in PAVmed’s flagship diagnostic tools like the EsoGuard test and digital health platforms through subsidiary Veris Health.
Bookmark this page for streamlined access to verified information directly from corporate communications. Check regularly for updates on PAVmed’s progress in commercializing technologies designed to improve early disease detection and patient care delivery.
Lucid Diagnostics (Nasdaq: LUCD) announced that a consortium of academic medical centers has received an $8 million NIH R01 grant for a five-year clinical study of its EsoCheck® and EsoGuard® technologies. The study will evaluate esophageal precancer detection in at-risk individuals without GERD symptoms.
The research, led by investigators from Case Western Reserve University and University Hospitals, will involve 800 patients across five research centers. The study aims to improve Barrett's Esophagus (BE) detection in non-GERD at-risk populations, who account for nearly half of esophageal cancer cases but are currently excluded from screening guidelines.
The study could potentially expand EsoGuard's target population for esophageal precancer testing. The technology was originally developed at CWRU and UH, with Lucid licensing the technologies exclusively in 2018.
Lucid Diagnostics (Nasdaq: LUCD) has successfully regained compliance with Nasdaq's minimum bid price requirement, the company announced on February 25, 2025. The commercial-stage cancer prevention medical diagnostics company, a subsidiary of PAVmed Inc. (Nasdaq: PAVM), had previously been notified of non-compliance for failing to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
To resolve this issue, Lucid was required to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive trading days, a condition that was satisfied on February 21, 2025. Following this achievement, the company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "LUCD".
PAVmed (PAVM) and its subsidiary Veris Health have completed a $2.37 million private placement financing. The deal includes PAVmed securities priced at-the-market and Veris common stock at a $35 million pre-money valuation.
This financing, combined with a recently secured $1.8 million non-dilutive two-year NIH grant, will fund the development of Veris' implantable physiological monitor. The company aims to enhance personalized cancer care through early detection of complications and reduced unplanned hospitalizations.
The financing represents a strategic milestone for Veris Health's commercial strategy, including regulatory clearance and launch of its implantable physiological monitor. Management believes the Veris pre-money valuation demonstrates strong investor confidence in the company's long-term commercial potential.
Lucid Diagnostics (LUCD) has signed its first concierge medicine contract with LEAA Health, enabling LEAA's membership-based patients to access EsoGuard® Esophageal DNA Test for esophageal precancer testing on a cash-pay basis. This strategic move aims to generate contractually-guaranteed revenue by tapping into the growing concierge medicine market, which is projected to reach $10.9 billion by 2032.
The partnership aligns with Lucid's strategy to expand EsoGuard revenue streams while pursuing Medicare and commercial coverage. LEAA Health will incorporate EsoGuard testing into its enhanced personalized care services, focusing on early detection and preventive healthcare. The collaboration represents a significant step in making innovative precancer detection tools more accessible to patients seeking premium healthcare services.
PAVmed (NASDAQ: PAVM, PAVMZ) has successfully regained compliance with Nasdaq Capital Market's Continued Listing Standards after receiving written notification from Nasdaq's Listing Qualifications Department on February 14, 2025. The company met the requirement of maintaining stockholders' equity of at least $2.5 million under Listing Rule 5550(b)(1).
The compliance was achieved through strategic initiatives, including the deconsolidation of Lucid Diagnostics subsidiary and restructuring of convertible debt. PAVmed will be subject to a mandatory panel monitor for one year, during which any non-compliance with stockholders' equity requirements will result in a delisting letter, requiring prompt attention and a potential new hearing.
Lucid Diagnostics (Nasdaq: LUCD), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), has announced its participation in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The conference is scheduled for February 11-12, 2024, at the Cliff Lodge in Snowbird, UT.
Shaun O'Neil, who serves as Lucid's President and Chief Operating Officer, will be available for one-on-one meetings throughout the conference. Interested investors are advised to contact their BTIG representative to schedule meetings.
Lucid Diagnostics (LUCD) reported record-breaking quarterly performance for its EsoGuard® Esophageal DNA Tests in Q4 2024, with 4,042 tests completed. This represents a 45% increase from Q3 2024 and an 84% year-over-year growth from Q4 2023.
The company is focusing on three key commercial revenue drivers: traditional claims submissions, direct contracting with employers and self-insured entities, and a new cash pay program targeting concierge medicine practices. Lucid aims to secure Medicare coverage and expects these initiatives to boost revenue growth and expand EsoGuard testing accessibility.
Full financial results for Q4 and full-year 2024 are expected to be released in mid-March 2025. The current figures are preliminary and subject to quarter-end closing and audit procedures.
Lucid Diagnostics (Nasdaq: LUCD) has received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement. The company now has until June 16, 2025 to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. The notification does not immediately affect LUCD's listing status, and shares will continue trading on the Nasdaq Capital Market. The company plans to take appropriate actions to regain compliance before the deadline.
Lucid Diagnostics (LUCD) has formed a strategic partnership with VITALExam to enhance access to its EsoGuard® Esophageal DNA Test for firefighters at risk of esophageal precancer. The partnership launched with a #CheckYourFoodTube Precancer Testing Event at Tuscaloosa Fire Rescue, as part of Lucid's expanded direct contracting initiative aimed at driving near-term EsoGuard revenue.
The collaboration is particularly significant as firefighters face a 62% increased risk of developing esophageal cancer and a 39% increased risk of dying from it. VITALExam, founded by Dr. Marci Vitale, specializes in providing comprehensive medical care for first responders, including cancer screenings and comprehensive physicals.
Lucid Diagnostics (NASDAQ: LUCD) announced the acceptance of its CLUE study manuscript for publication in Medicina, marking the fourth peer-reviewed publication supporting EsoGuard's clinical utility. The study demonstrated exceptional results, including 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard testing.
The prospective, multicenter study enrolled 502 patients across eight clinical centers, showing strong provider decision impact: 100% of EsoGuard-positive patients were referred for confirmatory EGD, while over 99% of EsoGuard-negative patients were not referred. The compliance rate was more than double the typical screening EGD referral rate in published literature.
FAQ
What is the current stock price of Pavmed (PAVM)?
What is the market cap of Pavmed (PAVM)?
